|
1
|
Sherr CJ: D-type cyclins. Trends Biochem
Sci. 20:187–190. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Banks PM, Chan J, Cleary ML, Delsol G, De
Wolf-Peeters C, Gatter K, Grogan TM, Harris NL, Isaacson PG, Jaffe
ES, et al: Mantle cell lymphoma. A proposal for unification of
morphologic, immunologic, and molecular data. Am J Surg Pathol.
16:637–640. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartkova J, Lukas J, Strauss M and Bartek
J: Cell cycle-related variation and tissue-restricted expression of
human cyclin D1 protein. J Pathol. 172:237–245. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salaverria I, Royo C, Carvajal-Cuenca A,
Clot G, Navarro A, Valera A, Song JY, Woroniecka R, Rymkiewicz G,
Klapper W, et al: CCND2 rearrangements are the most frequent
genetic events in cyclin D1(−) mantle cell lymphoma. Blood.
121:1394–1402. 2013. View Article : Google Scholar :
|
|
6
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of
Tumours of Hematopoietic and Lymphoid Tissues. 4th edition. IARC;
Lyon, France: 2008
|
|
7
|
Ye BH, Rao PH, Chaganti RS and
Dalla-Favera R: Cloning of bcl-6, the locus involved in chromosome
translocations affecting band 3q27 in B-cell lymphoma. Cancer Res.
53:2732–2735. 1993.PubMed/NCBI
|
|
8
|
Gascoyne RD, Adomat SA, Krajewski S,
Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P,
Coldman AJ, Reed JC, et al: Prognostic significance of Bcl-2
protein expression and Bcl-2 gene rearrangement in diffuse
aggressive non-Hodgkin's lymphoma. Blood. 90:244–251.
1997.PubMed/NCBI
|
|
9
|
Savage KJ, Johnson NA, Ben-Neriah S,
Connors JM, Sehn LH, Farinha P, Horsman DE and Gascoyne RD: MyC
gene rearrangements are associated with a poor prognosis in diffuse
large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Blood. 114:3533–3537. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barrans S, Crouch S, Smith A, Turner K,
Owen R, Patmore R, Roman E and Jack A: Rearrangement of MYC is
associated with poor prognosis in patients with diffuse large
B-cell lymphoma treated in the era of rituximab. J Clin Oncol.
28:3360–3365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu-Monette ZY, Wu L, Visco C, Tai YC,
Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, et
al: Mutational profile and prognostic significance of TP53 in
diffuse large B-cell lymphoma patients treated with R-CHOP: Report
from an International DLBCL Rituximab-CHOP Consortium Program
Study. Blood. 120:3986–3996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lossos IS, Czerwinski DK, Alizadeh AA,
Wechser MA, Tibshirani R, Botstein D and Levy R: Prediction of
survival in diffuse large-B-cell lymphoma based on the expression
of six genes. N Engl J Med. 350:1828–1837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horn H, Ziepert M, Becher C, Barth TF,
Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, et
al German High-Grade Non-Hodgkin Lymphoma Study Group: MyC status
in concert with BCL2 and BCL6 expression predicts outcome in
diffuse large B-cell lymphoma. Blood. 121:2253–2263. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ehinger M, Linderoth J, Christensson B,
Sander B and Cavallin-Ståhl E: A subset of CD5- diffuse large
B-cell lymphomas expresses nuclear cyclin D1 with aberrations at
the CCND1 locus. Am J Clin Pathol. 129:630–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodriguez-Justo M, Huang Y, Ye H, Liu H,
Chuang SS, Munson P, Prada-Puentes C, Kim I, Du MQ and Bacon CM:
Cyclin D1-positive diffuse large B-cell lymphoma. Histopathology.
52:900–903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Teruya-Feldstein J, Gopalan A and
Moskowitz CH: CD5 negative, cyclin D1-positive diffuse large B-cell
lymphoma (DLBCL) presenting as ruptured spleen. Appl
Immunohistochem Mol Morphol. 17:255–258. 2009. View Article : Google Scholar
|
|
18
|
Metcalf RA, Zhao S, Anderson MW, Lu ZS,
Galperin I, Marinelli RJ, Cherry AM, Lossos IS and Natkunam Y:
Characterization of D-cyclin proteins in hematolymphoid neoplasms:
Lack of specificity of cyclin-D2 and D3 expression in lymphoma
subtypes. Mod Pathol. 23:420–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lucioni M, Novara F, Riboni R, Fiandrino
G, Nicola M, Kindl S, Boveri E, Jemos V, Arcaini L, Zuffardi O, et
al: CD5(−) diffuse large B-cell lymphoma with peculiar cyclin
D1+ phenotype. Pathologic and molecular characterization
of a single case. Hum Pathol. 42:1204–1208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vela-Chávez T, Adam P, Kremer M, Bink K,
Bacon CM, Menon G, Ferry JA, Fend F, Jaffe ES and
Quintanilla-Martínez L: Cyclin D1 positive diffuse large B-cell
lymphoma is a post-germinal center-type lymphoma without
alterations in the CCND1 gene locus. Leuk Lymphoma. 52:458–466.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsiao SC, Cortada IR, Colomo L, Ye H, Liu
H, Kuo SY, Lin SH, Chang ST, Kuo TU, Campo E, et al: SOX11 is
useful in differentiating cyclin D1-positive diffuse large B-cell
lymphoma from mantle cell lymphoma. Histopathology. 61:685–693.
2012.PubMed/NCBI
|
|
22
|
Hans CP, Weisenburger DD, Greiner TC, Chan
WC, Aoun P, Cochran GT, Pan Z, Smith LM, Lynch JC, Bociek RG, et
al: Expression of PKC-beta or cyclin D2 predicts for inferior
survival in diffuse large B-cell lymphoma. Mod Pathol.
18:1377–1384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Amen F, Horncastle D, Elderfield K, Banham
AH, Bower M, Macdonald D, Kanfer E and Naresh KN: Absence of
cyclin-D2 and Bcl-2 expression within the germinal centre type of
diffuse large B-cell lymphoma identifies a very good prognostic
subgroup of patients. Histopathology. 51:70–79. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Igawa T, Sato Y, Takata K, Iwaki N, Tanaka
T, Asano N, Maeda Y, Orita Y, Nakamura N, Nakamura S, et al: De
novo CD5-positive diffuse large B-cell lymphomas show high
specificity for cyclin D2 expression. Diagn Pathol. 8:812013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi M, Seto M, Okamoto M,
Ichinohasama R, Nakamura N, Yoshino T, Suzumiya J, Murase T, Miura
I, Akasaka T, et al: De novo CD5+ diffuse large B-cell
lymphoma: A clinicopathologic study of 109 patients. Blood.
99:815–821. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Filipits M, Jaeger U, Pohl G, Stranzl T,
Simonitsch I, Kaider A, Skrabs C and Pirker R: Cyclin D3 is a
predictive and prognostic factor in diffuse large B-cell lymphoma.
Clin Cancer Res. 8:729–733. 2002.PubMed/NCBI
|
|
27
|
Stefancikova L, Moulis M, Fabian P,
Falkova I, Vasova I, Kren L, Macak J and Smardova J: Complex
analysis of cyclin D1 expression in mantle cell lymphoma: Two
cyclin D1-negative cases detected. J Clin Pathol. 62:948–950. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar
|
|
29
|
Muris JJF, Meijer CJLM, Vos W, van Krieken
JH, Jiwa NM, Ossenkoppele GJ and Oudejans JJ: Immunohistochemical
profiling based on Bcl-2, CD10 and MUM1 expression improves risk
stratification in patients with primary nodal diffuse large B cell
lymphoma. J Pathol. 208:714–723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matsuo Y, Drexler HG, Harashima A, Okochi
A, Hasegawa A, Kojima K and Orita K: Induction of CD28 on the new
myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing
delta/lambda type immunoglobulin. Leuk Res. 28:869–877. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Szepesi A, Gelfand EW and Lucas JJ:
Association of proliferating cell nuclear antigen with
cyclin-dependent kinases and cyclins in normal and transformed
human T lymphocytes. Blood. 84:3413–3421. 1994.PubMed/NCBI
|
|
32
|
Bijwaard KE, Aguilera NS, Monczak Y,
Trudel M, Taubenberger JK and Lichy JH: Quantitative real-time
reverse transcription-PCR assay for cyclin D1 expression: Utility
in the diagnosis of mantle cell lymphoma. Clin Chem. 47:195–201.
2001.PubMed/NCBI
|
|
33
|
Hui P, Howe JG, Crouch J, Nimmakayalu M,
Qumsiyeh MB, Tallini G, Flynn SD and Smith BR: Real-time
quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma:
Comparison with FISH and immunohistochemistry. Leuk Lymphoma.
44:1385–1394. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brizova H, Kalinova M, Krskova L, Mrhalova
M and Kodet R: Quantitative measurement of cyclin D1 mRNA, a potent
diagnostic tool to separate mantle cell lymphoma from other B-cell
lymphoproliferative disorders. Diagn Mol Pathol. 17:39–50.
2008.PubMed/NCBI
|
|
35
|
Cao X, Fan L, Fang C, Zhu DX, Dong HJ,
Wang DM, Wang YH, Xu W and Li JY: The expression of SOX11, cyclin
D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative
diseases. Med Oncol. 29:1190–1196. 2012. View Article : Google Scholar
|
|
36
|
Quintanilla-Martinez L, Slotta-Huspenina
J, Koch I, Klier M, Hsi ED, de Leval L, Klapper W, Gesk S, Siebert
R and Fend F: Differential diagnosis of cyclin D2+
mantle cell lymphoma based on fluorescence in situ hybridization
and quantitative real-time-PCR. Haematologica. 94:1595–1598. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Teramoto N, Pokrovskaja K, Szekely L,
Polack A, Yoshino T, Akagi T and Klein G: Expression of cyclin D2
and D3 in lymphoid lesions. Int J Cancer. 81:543–550. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Møller MB, Nielsen O and Pedersen NT:
Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with
other cell cycle regulators and clinical features. Am J Clin
Pathol. 115:404–412. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ok CY, Xu-Monette ZY, Tzankov A, O'Malley
DP, Montes-Moreno S, Visco C, Møller MB, Dybkaer K, Orazi A, Zu Y,
et al: Prevalence and clinical implications of cyclin D1 expression
in diffuse large B-cell lymphoma (DLBCL) treated with
immunochemotherapy: A report from the International DLBCL
Rituximab-CHOP Consortium Program. Cancer. 120:1818–1829. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Juskevicius D, Ruiz C, Dirnhofer S and
Tzankov A: Clinical, morphologic, phenotypic, and genetic evidence
of cyclin D1-positive diffuse large B-cell lymphomas with CYCLIN D1
gene rearrangements. Am J Surg Pathol. 38:719–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bai M, Tsanou E, Agnantis NJ, Chaidos A,
Dimou D, Skyrlas A, Dimou S, Vlychou M, Galani V and Kanavaros P:
Expression of cyclin D3 and cyclin E and identification of distinct
clusters of proliferation and apoptosis in diffuse large B-cell
lymphomas. Histol Histopathol. 18:449–457. 2003.PubMed/NCBI
|
|
42
|
Malumbres R, Chen J, Tibshirani R, Johnson
NA, Sehn LH, Natkunam Y, Briones J, Advani R, Connors JM, Byrne GE,
et al: Paraffin-based 6-gene model predicts outcome in diffuse
large B-cell lymphoma patients treated with R-CHOP. Blood.
111:5509–5514. 2008. View Article : Google Scholar : PubMed/NCBI
|
